These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15198179)

  • 1. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.
    Hansen BR; Haugaard SB; Iversen J; Nielsen JO; Andersen O
    Scand J Infect Dis; 2004; 36(4):244-53. PubMed ID: 15198179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching effective antiretroviral therapy: a review.
    Drechsler H; Powderly WG
    Clin Infect Dis; 2002 Nov; 35(10):1219-30. PubMed ID: 12410482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body-fat abnormalities in patients with HIV: progress and challenges.
    Bedimo RJ
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):292-305. PubMed ID: 19056708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyên TH; Adda N; Rozenbaum W; Capeau J
    Diabetes Metab; 1999 Nov; 25(5):383-92. PubMed ID: 10592860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
    Senise JF; Castelo A; Martínez M
    AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch strategies in patients on effective HAART.
    Maggiolo F; Ripamonti D; Suter F
    J Antimicrob Chemother; 2005 Jun; 55(6):821-3. PubMed ID: 15849261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.
    Barreiro P; García-Benayas T; Soriano V; Gallant J
    AIDS Rev; 2002; 4(4):233-41. PubMed ID: 12555697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
    Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J
    Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
    Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
    AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choosing the right initial antiretroviral regimens.
    Norton M
    GMHC Treat Issues; 1999 Feb; 13(2):7-10. PubMed ID: 11366117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of switching to protease inhibitor monotherapy on nucleoside analogue-related adverse events.
    Clumeck N; Hill A; Moecklinghoff C
    AIDS Rev; 2014; 16(4):236-45. PubMed ID: 25350532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
    Carr A; Miller J; Law M; Cooper DA
    AIDS; 2000 Feb; 14(3):F25-32. PubMed ID: 10716495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
    Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
    Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.
    Bucher HC; Young J; Battegay M
    J Antimicrob Chemother; 2004 Aug; 54(2):303-5. PubMed ID: 15269200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.